Citadel Advisors
IRWD icon

Citadel Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Citadel Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$383K Buy
109,200
+95,500
+697% +$391K ﹤0.01% 9903
2025
Q4 		$46.2K Buy
13,700
+2,000
+17% +$5.19K ﹤0.01% 12067
2025
Q3 		$15.3K Buy
+11,700
New +$12.1K ﹤0.01% 12531
2025
Q2 		– Sell
-6,900
Closed -$10.1K – 13774
2025
Q1 		$10.1K Buy
6,900
+4,100
+146% +$9.77K ﹤0.01% 13555
2024
Q4 		$12.4K Sell
2,800
-6,300
-69% -$25.6K ﹤0.01% 13499
2024
Q3 		$37.5K Sell
9,100
-7,200
-44% -$38.7K ﹤0.01% 12216
2024
Q2 		$106K Sell
16,300
-149,000
-90% -$1.05M ﹤0.01% 10829
2024
Q1 		$1.44M Buy
165,300
+159,200
+2,610% +$1.93M ﹤0.01% 6169
2023
Q4 		$69.8K Sell
6,100
-1,200
-16% -$11.9K ﹤0.01% 11390
2023
Q3 		$70.3K Buy
7,300
+4,300
+143% +$42.1K ﹤0.01% 11321
2023
Q2 		$31.9K Buy
3,000
+300
+11% +$3.22K ﹤0.01% 12284
2023
Q1 		$28.4K Buy
2,700
+600
+29% +$6.72K ﹤0.01% 12786
2022
Q4 		$26K Buy
+2,100
New +$23.8K ﹤0.01% 12903
2022
Q2 		– Sell
-24,200
Closed -$304K – 13474
2022
Q1 		$304K Sell
24,200
-5,700
-19% -$65.3K ﹤0.01% 10565
2021
Q4 		$349K Sell
29,900
-35,300
-54% -$433K ﹤0.01% 10574
2021
Q3 		$852K Sell
65,200
-12,200
-16% -$158K ﹤0.01% 8546
2021
Q2 		$996K Sell
77,400
-42,600
-36% -$488K ﹤0.01% 8382
2021
Q1 		$1.34M Buy
120,000
+102,500
+586% +$1.08M ﹤0.01% 7380
2020
Q4 		$199K Buy
17,500
+4,200
+32% +$46K ﹤0.01% 9733
2020
Q3 		$120K Sell
13,300
-7,300
-35% -$72.6K ﹤0.01% 9160
2020
Q2 		$213K Sell
20,600
-2,100
-9% -$21.5K ﹤0.01% 8439
2020
Q1 		$229K Buy
22,700
+2,600
+13% +$30.6K ﹤0.01% 7785
2019
Q4 		$268K Buy
+20,100
New +$222K ﹤0.01% 7773
2019
Q1 		– Sell
-22,447
Closed -$195K – 9573
2018
Q4 		$195K Sell
22,447
-3,940
-15% -$45.2K ﹤0.01% 7885
2018
Q3 		$408K Buy
26,387
+1,313
+5% +$20.8K ﹤0.01% 7029
2018
Q2 		$402K Buy
+25,074
New +$371K ﹤0.01% 6729
2015
Q4 		– Sell
-3,224
Closed -$28K – 8934
2015
Q3 		$28K Sell
3,224
-1,910
-37% -$17.8K ﹤0.01% 7966
2015
Q2 		$52K Buy
5,134
+3,462
+207% +$40.2K ﹤0.01% 7631
2015
Q1 		$22K Buy
1,672
+120
+8% +$1.57K ﹤0.01% 7845
2014
Q4 		$20K Sell
1,552
-10,149
-87% -$116K ﹤0.01% 7797
2014
Q3 		$127K Buy
11,701
+9,074
+345% +$104K ﹤0.01% 6186
2014
Q2 		$34K Sell
2,627
-9,791
-79% -$106K ﹤0.01% 7006
2014
Q1 		$128K Buy
12,418
+10,985
+767% +$124K ﹤0.01% 5949
2013
Q4 		$14K Sell
1,433
-358
-20% -$3.21K ﹤0.01% 6623
2013
Q3 		$18K Sell
1,791
-10,865
-86% -$107K ﹤0.01% 6264
2013
Q2 		$105K Buy
+12,656
New +$153K ﹤0.01% 5190

Other funds holding IRWD

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's IRWD Position: Q1 2026 in Review

Citadel Advisors reduced its Ironwood Pharmaceuticals (IRWD) stake by 47% in Q1 2026, selling an estimated $433K and leaving 118,276 shares worth $415K. The position accounts for ﹤0.01% of the portfolio, ranked #9743.

Citadel Advisors first reported a position in IRWD in Q2 2013 and has held it in 43 quarters since. The position peaked at $45.4M in Q2 2019. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.

  • Citadel Advisors held 118,276 shares of Ironwood Pharmaceuticals worth $415K as of Q1 2026.
  • Citadel Advisors sold 105,693 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $433K.
  • Ironwood Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9743 holding.
  • Citadel Advisors first reported a position in Ironwood Pharmaceuticals in Q2 2013 and has held it in 43 quarters since.
  • Citadel Advisors's Ironwood Pharmaceuticals position peaked at $45.4M in Q2 2019.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.